CN105121431A - Improved process for the manufacture of moxonidine - Google Patents
Improved process for the manufacture of moxonidine Download PDFInfo
- Publication number
- CN105121431A CN105121431A CN201480013663.5A CN201480013663A CN105121431A CN 105121431 A CN105121431 A CN 105121431A CN 201480013663 A CN201480013663 A CN 201480013663A CN 105121431 A CN105121431 A CN 105121431A
- Authority
- CN
- China
- Prior art keywords
- moxonidine
- less
- preparation
- dmaia
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention describes a novel process for the preparation of Moxonidine (Formula (I)).
Description
Technical field
The present invention relates to the novel method for the preparation of moxonidine (Moxonidine).
Background technology
The chloro-N-of 4-(imidazolidine-2-subunit)-6-methoxyl group-2-methylpyrimidine-5-amine has International Non-Proprietary Name (INN) moxonidine, and is used as antihypertensive drug.It has structural formula (I):
Moxonidine can by key intermediate, 4,6-bis-chloro-2-methyl-5-(1-ethanoyl-2-tetrahydroglyoxaline-2-base) aminopyrimidine (hereinafter referred to as DMAIA) preparation of structural formula (II):
U.S. Patent No. 4,323,570 disclose the method by making formula (II) compound and sodium methylate react to prepare moxonidine (I).
In CZ294649, disclose by using the reaction of alkaline carbonate to prepare the method for moxonidine by DMAIA in methyl alcohol.
EP1873151 proposes and uses alkali (such as sodium hydroxide and potassium hydroxide) for the reaction with DMAIA.
Challenge main in the reaction of DMAIA to moxonidine is the generation of some by products.European Pharmacopoeia (Ph.Eur.) lists following major impurity:
The chloro-N-of impurity A: 4,6-bis-(imidazolidine-2-subunit)-2-methylpyrimidine-5-amine (6-chlorine moxonidine):
Impurity B: N-(imidazolidine-2-subunit)-4,6-dimethoxy-2-methylpyrimidine-5-amine (4-methoxyl group-moxonidine):
Impurity C:5-[(imidazolidine-2-subunit) is amino]-6-methoxyl group-2-methylpyrimidine-4-alcohol (4-hydroxyl moxonidine):
The chloro-5-of impurity D:6-[(imidazolidine-2-subunit) is amino]-2-methylpyrimidine-4-alcohol (6-demethyl moxonidine)
Light absorbing impurty set by European Pharmacopoeia 7.0 is as follows:
Impurity A: be no more than 0.3%
Impurity B: be no more than 0.3%
Impurity C and D: be no more than 0.1%
Total impurities: be no more than 0.5%
Be it seems by disclosed method in the prior art, in order to meet the requirement of European Pharmacopoeia about impurity A and B, other re-crystallization step is enforceable.Such as, in 36 working examples altogether of EP1873151, the moxonidine (both include re-crystallization step) that only with good grounds example 34 and 36 obtains meets the limitation of impurity A and B.
The reason being difficult to simultaneously obtain low-level impurity A and B is obvious by figure below:
To be it is believed that to the reaction cascade of moxonidine by DMAIA and comprise the first de-acetyl step, cause forming " impurity A ".In the first step of replacing, first in two chlorine atoms, subsequently by the methoxy substitution from solvent methanol, produces moxonidine.In continuous print step of replacing, another chlorine substituent also by another methoxy substitution, directly produces impurity B.Be apparent that immediately by Fig. 1, impurity A is some " underaction " compared with moxonidine, because only there is acyl group to remove from DMAIA, and two Cl atoms still retain.On the other hand, can say impurity B compared with moxonidine some " overreact ", because not only a Cl substituting group is replaced (as in moxonidine) by methoxy substitution base, but two are all substituted.
Be it seems by prior art, the moxonidine with a small amount of impurity A and a small amount of impurity B may be produced hardly.If the reaction times is short, a large amount of hyporeactive impurity A can be left.On the other hand, the impurity B that the reaction times inevitably produces " overreact " is in a large number extended.When reduce impurity A and raising impurity B be formed with indivisible contact, other crystallisation step must be applied to meet the requirement of European Pharmacopoeia as above.
About impurity C and D, prior art is not mentioned.But, it is believed that at least for the EP1873151 employing hydroxide bases (such as NaOH and KOH), it is expected to the remarkable formation of hydroxyl impurity C and D.
In addition, the not open method of synthesizing moxonidine on a commercial scale of prior art document.Prior art only discloses the lot-size of several grams.
Therefore, the moxonidine that production quality is on a commercial scale good is needed.
For above-mentioned reasons, very surprisingly present inventor has found the robust method of synthesizing moxonidine in kg scale with high yield and the purity (not having other re-crystallization step) meeting European Pharmacopoeia requirement.
Summary of the invention
The invention provides commercial production moxonidine and do not need the method for other crystallisation step, it comprises the following steps:
-suspension of weak base in methyl alcohol is provided at the temperature of 50 DEG C to 65 DEG C
-DMAIA is divided into some parts be added into suspension
-after the interpolation completing DMAIA, be less than one hour again under mixture is remained on this temperature of reaction
-reaction mixture is cooled to lower than 30 DEG C being less than in 30 minutes
Suitable weak base can be selected from but be not limited to: salt of wormwood, sodium bicarbonate, sodium carbonate, saleratus, Quilonum Retard, cesium carbonate, lithium bicarbonate, cesium bicarbonate and composition thereof.
Because highly basic (such as alkali methylates or alkali metal hydroxide) significantly accelerates by DMAIA to the conversion of its substitution product, present method can not be applied to the reaction containing this quasi-alkali.
Salt of wormwood and/or sodium carbonate are preferred alkali, because it does not produce the water of the amount that can cause impurity C and D improved.Most preferred alkali is salt of wormwood.
Preferably, the mol ratio of weak base and DMAIA is in the scope of 1.95 to the 2.05 equivalent weak base relative to DMAIA.Use and be less than 1.95 times of excessive alkali (as EP1873151 institute proposes) and cause in reducing and the ability of hydrochloric acid (producing after replacement is from the chlorine atom of DMAIA), and caused the reaction times required for reaction to extend, and the amount of the impurity B of " overreact " that improve.On the other hand, use the alkali excessive relative to DMAIA > 2.05 times to cause forming more substantial inorganic salt, it unnecessarily makes workflow complicated.
Preferred use is relative to 100 to 120 times of molar excess of DMAIA, the preferably methyl alcohol of 110 to 120 times of molar excess.Importantly recognize and regulate the methanol content relevant with the content of DMAIA and alkali not to be simple one-parameter optimization because methyl alcohol is not only as solvent, and while as reagent.In addition, DMAIA and carbonate bases are only partly dissolved in methyl alcohol, and therefore reacting is not occur in the solution, but embody the suspension reaction in heterogeneous with heterogeneous equilibrium.
In order to accelerate as far as possible by DMAIA to the conversion of moxonidine, temperature of reaction preferably remains near the boiling point of methyl alcohol, namely in the scope of 60 DEG C to 65 DEG C.
Optionally DMAIA can be divided into 2 to 20 parts under this temperature of reaction, preferably 5 to 15 parts, even more preferably 8 to 10 parts are added into the suspension of suitable weak base in methyl alcohol.Consider that the reaction of DMAIA is heat release and occurs in suspension, the technique effect adding continuously the DMAIA of portioning keeps temperature of reaction constant and avoid producing agglomerate.
After interpolation DMAIA, mixture is preferably kept to less than 30 minutes at the reaction temperatures, more preferably 5 to 20 minutes, and most preferably 7 to 12 minutes to complete by DMAIA to the conversion of moxonidine, but avoid overreact.
In order to faster and more efficiently stopped reaction, reaction mixture is cooled to lower than 30 DEG C being less than in 30 minutes subsequently, is more preferably cooled to lower than 25 DEG C being less than in 30 minutes, and is even more preferably cooled to lower than 25 DEG C being less than in 20 minutes.
Optionally, reaction mixture, in 5 minutes or less time, preferably in 3 minutes or less time, is even more preferably additionally transferred to second through pre-cooled reactor being less than in 1 minute.
Optionally, process of cooling is strengthened further by frozen water and/or ice cube, liquid nitrogen, dry ice etc. being embedded in (inserting) to container.
Precipitation and the further work flow process of moxonidine can be carried out as described in the prior art.
As the result of whole method, create some advantages:
-total reaction time is significantly reduced to only several minutes by a few hours and a couple of days
-the most important thing is, level (especially impurity A and the N-(imidazolidine-2-subunit)-4 of impurity, the level of 6-dimethoxy-2-methylpyrimidine-5-amine (impurity B)) be reduced to far below 0.3%, and total impurities is reduced to far below 0.5%, thus meet the requirement of European Pharmacopoeia, and do not need crystallisation step that is other, time consumption and energy consumption, as shown in table 1.
Finally, aforesaid method is also suitable on a commercial scale (namely comprise 1kg or more DMAIA batch) high productivity and produces.
the preparation of preparation embodiment 1 to 3-moxonidine
By 102kg (128L, 3014.4mol) methyl alcohol and 7.7kg (55.6mol) salt of wormwood injecting reactor, mixture is stirred vigorously and is heated to 65 DEG C.8kgDMAIA (27.8mol) is divided into 8 parts to add in 20 minutes.The content of reactor under agitation remain on 65 DEG C other 7 to 12 minutes.By independent reaction mixture be cooled to further in 20 minutes and carry out stopped reaction through pre-cooled reactor lower than 25 DEG C being less than in 1 minute complete reaction mixture to be transferred to.
workflow:
PH value acetic acid is adjusted to pH≤7.Reaction mixture is optionally by activated carbon filtration.Then the pH ammonia soln of filtrate is adjusted to pH >=8, and is separated moxonidine, use water and methanol wash and drying.
productive rate:in theory 92.0%
table 1: the moxonidine impurity measured according to European Pharmacopoeia 7.0
In European Pharmacopoeia 7.0, impurity is measured by the HPLC method wherein set up, and % content is determined by the peak area of each impurity and the peak of reference standard solution being compared.
Claims (15)
1., for the preparation of the method for moxonidine, it comprises the following steps:
-suspension of weak base in methyl alcohol is provided at the temperature of 50 DEG C to 65 DEG C
-DMAIA is divided into some parts be added into described suspension
-after the interpolation completing DMAIA, be less than one hour again under mixture is remained on this temperature of reaction
-reaction mixture is cooled to lower than 30 DEG C being less than in 30 minutes.
2. the method for the preparation of moxonidine according to claim 1, wherein said weak base relative to DMAIA with 1.95 to 2.05 mol ratio exist.
3. according to the method for the preparation of moxonidine according to claim 1 or claim 2, wherein said weak base is selected from following one: salt of wormwood, sodium bicarbonate, sodium carbonate, saleratus, Quilonum Retard, cesium carbonate, lithium bicarbonate, cesium bicarbonate or its mixture.
4. the method for the preparation of moxonidine according to claim 3, wherein said weak base is selected from following one: salt of wormwood, sodium carbonate or its mixture.
5. according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein be less than in 1 hour with 2 to 20 parts, preferably be less than in 30 minutes with 5 to 15 parts, most preferably be less than in 20 minutes with 8 to 10 parts add DMAIA.
6. according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein methanol phase exists with the molar excess of 80 to 150 times for DMAIA, preferably exist with the molar excess of 100 to 130 times relative to DMAIA, most preferably exist with the molar excess of 110 to 120 times relative to DMAIA.
7., according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein said temperature of reaction remains on 60 DEG C to 65 DEG C.
8., according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein after the interpolation completing DMAIA, described mixture is kept to less than 30 minutes under described temperature of reaction, preferably 5 to 20 minutes, most preferably 7 to 12 minutes.
9. according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein said reaction mixture is cooled to lower than 25 DEG C being less than in 30 minutes, and is preferably cooled to lower than 25 DEG C being less than in 20 minutes.
10., according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein process of cooling is strengthened by frozen water and/or ice cube, liquid nitrogen or dry ice being embedded in container.
11. according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein said reaction mixture is in 5 minutes or less time, preferably in 3 minutes or less time, more preferably be less than in 1 minute be transferred to independent in pre-cooled reactor.
12. is commercial-scale according to the method for the preparation of moxonidine in any one of the preceding claims wherein, and wherein the amount of DMAIA is 5kg or more.
13. according to the method for the preparation of moxonidine in any one of the preceding claims wherein, wherein when measuring according to European Pharmacopoeia 7.0, the moxonidine obtained comprise 4,-2-methylpyrimidine-5-amine (impurity A) is less than 0.05% and N-(imidazolidine-2-subunit)-4 for the chloro-N-of 6-bis-(imidazolidine-2-subunit), 6-dimethoxy-2-methylpyrimidine-5-amine (impurity B) is 0.18% or less, and total impurities is 0.28% or less.
14. moxonidines obtained when not having further recrystallization according to one of aforementioned claim, wherein when measuring according to European Pharmacopoeia 7.0, described moxonidine comprise 4,-2-methylpyrimidine-5-amine (impurity A) is less than 0.3% and N-(imidazolidine-2-subunit)-4,6-dimethoxy-2-methylpyrimidine-5-amine (impurity B) is less than 0.3% for the chloro-N-of 6-bis-(imidazolidine-2-subunit).
15. moxonidines obtained when not having further recrystallization according to one of aforementioned claim, wherein when measuring according to European Pharmacopoeia 7.0, described moxonidine comprise 4,-2-methylpyrimidine-5-amine (impurity A) is less than 0.05% and N-(imidazolidine-2-subunit)-4 for the chloro-N-of 6-bis-(imidazolidine-2-subunit), 6-dimethoxy-2-methylpyrimidine-5-amine (impurity B) is 0.18% or less, and total impurities is 0.28% or less.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13001305 | 2013-03-14 | ||
| EP13001305.5 | 2013-03-14 | ||
| PCT/EP2014/054735 WO2014140034A1 (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105121431A true CN105121431A (en) | 2015-12-02 |
Family
ID=47900474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480013663.5A Pending CN105121431A (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2970214A1 (en) |
| CN (1) | CN105121431A (en) |
| IL (1) | IL240819A0 (en) |
| WO (1) | WO2014140034A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| CZ294649B6 (en) * | 2004-02-10 | 2005-02-16 | Farmak, A. S. | Process for preparing 4-chloro-N-(4,5-dihydro-1-H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
| EP1873151A1 (en) * | 2006-06-26 | 2008-01-02 | Chemagis Ltd. | Improved process for producing moxonidine |
-
2014
- 2014-03-11 WO PCT/EP2014/054735 patent/WO2014140034A1/en active Application Filing
- 2014-03-11 EP EP14709300.9A patent/EP2970214A1/en not_active Withdrawn
- 2014-03-11 CN CN201480013663.5A patent/CN105121431A/en active Pending
-
2015
- 2015-08-25 IL IL240819A patent/IL240819A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| CZ294649B6 (en) * | 2004-02-10 | 2005-02-16 | Farmak, A. S. | Process for preparing 4-chloro-N-(4,5-dihydro-1-H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
| EP1873151A1 (en) * | 2006-06-26 | 2008-01-02 | Chemagis Ltd. | Improved process for producing moxonidine |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014140034A1 (en) | 2014-09-18 |
| EP2970214A1 (en) | 2016-01-20 |
| IL240819A0 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103373989B (en) | The preparation method of the intermediate of pazopanib hydrochloride | |
| CN108558884B (en) | Synthesis method of folic acid | |
| CN104045602A (en) | Improved method for preparing tetrazole for valsartan | |
| CN110878084A (en) | Preparation method of nicosulfuron original drug | |
| AU2023203664B2 (en) | Method for preparing azoxystrobin and intermediate thereof | |
| CN103373963B (en) | Intermediate of pazopanib hydrochloride and preparation method of intermediate of pazopanib hydrochloride | |
| CN105121431A (en) | Improved process for the manufacture of moxonidine | |
| CN103333117A (en) | Preparation method of 4[(4-chloro-2-pyrmidyl)amino]cyanophenyl | |
| EP1937662A1 (en) | Process for the preparation of duloxetine | |
| WO2016202124A1 (en) | Riociguat intermediate and preparation method therefor | |
| CN1321975C (en) | Diethyl 4[(4-oxo-3-bromo) butyl] benzoyl-L-glutamate and preparation and use | |
| CN102211994A (en) | Industrialized synthesis method of 3-(2-bromophenyl)propionic acid | |
| CN104744537A (en) | Synthetic method of capecitabine | |
| EP3303277B1 (en) | Process for the synthesis of 9,9-bis(methoxymethyl)fluorene | |
| CN104725321A (en) | Preparation method of azoxystrobin intermediate | |
| CN111303045A (en) | Production process of 2-ethoxy-4, 6-difluoropyrimidine | |
| CN105503853A (en) | Synthetic method of cefdinir activated thioester | |
| US10392403B2 (en) | Process for preparing thienopyrimidine compound and intermediates used therein | |
| CA3136883A1 (en) | Process for the preparation of fungicidally active strobilurin compounds and intermediates thereof | |
| CN100376546C (en) | Diethyl 4(4-oxobutyl) benzoyl-L-glutamate and its preparation and use | |
| CN103922959A (en) | Method for preparing intermediate diethyl acetamidomalonate through organic synthesis | |
| CN104086553B (en) | One prepares the method for 7-bromine imidazo [2,1-f] [1,2,4] triazine-4-amine | |
| CN108976228A (en) | A kind of preparation method of 7- azaindole | |
| CN109206373A (en) | A kind of pa wins the preparation process of the chloro- 4- clopentylamino pyrimidine of the bromo- 2- of former times cloth intermediate 5- | |
| CN110981795B (en) | Method for preparing 2-aminoacyl isonicotinic acid by using methyl 2-cyanoisonicotinate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151202 |